SCHEMBL3275533

SCHEMBL3275533

O=C(NCC(=O)N1CCN(CCN2CCCCC2)CC1)c1ccc(S(=O)(=O)N(Oc2ccc(Cl)cc2Cl)c2ccccc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 3/20 0.44
PSEN1 P49768 3/20 0.41
PSEN2 P49810 3/20 0.41
APH1B Q8WW43 3/20 0.41
NCSTN Q92542 3/20 0.41
APH1A Q96BI3 3/20 0.41
PSENEN Q9NZ42 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CA12 O43570 1/20 0.40
CA9 Q16790 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
NPC1 O15118 1/20 0.40
F10 P00742 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
LMNA P02545 1/20 0.38
THRA P10827 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3274097 0.99 CCR2 (0.42) CCR2PSEN1PSEN2APH1BNCSTN
SCHEMBL3273929 0.97 PSEN1 (0.43) CCR2PSEN1PSEN2APH1BNCSTN
SCHEMBL3275589 0.96 PSEN1 (0.43) CCR2PSEN1PSEN2APH1BNCSTN
SCHEMBL3280575 0.95 PSEN1 (0.42) CCR2PSEN1PSEN2APH1BNCSTN
SCHEMBL15103791 0.94 SMN1; SMN2 (0.46) CCR2SMN1; SMN2MAPTNPC1GAA
SCHEMBL15104003 0.94 SMN1; SMN2 (0.46) CCR2SMN1; SMN2MAPTNPC1GAA
SCHEMBL15103873 0.93 ALDH1A1 (0.43) SMN1; SMN2CA12CA9KMT2AGAA
SCHEMBL15103984 0.93 SMN1; SMN2 (0.42) CCR2SMN1; SMN2MAPTNPC1F10
SCHEMBL15103883 0.93 NPC1 (0.46) SMN1; SMN2MAPTNPC1GAAHPGD
SCHEMBL15103943 0.92 F10 (0.42) SMN1; SMN2MAPTKMT2ANPC1F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2076491-B1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-07-17 EP claimed
US-8481527-B2 Benzamide derivatives as bradykinin antagonists RICHTER GEDEON NYRT. (HU) 2013-07-09 US claimed
US-20100087423-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-04-08 US claimed
EP-2076491-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS Richter Gedeon NYRT (HU) 2009-07-08 EP claimed
WO-2008068540-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2008-06-12 WO claimed
EP-2076491-B1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-07-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087423-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, HRH1 CCR2 380/4885PSEN1 2019/4885PSEN2 3099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.